九強生物(300406.SZ):擬18.03億元收購邁新生物65.55%的股權
格隆匯6月12日丨九強生物(300406.SZ)公佈,公司擬與國藥投資共同採用支付現金方式購買德福二期、GL、杭州鼎暉、泰康人壽、廣州盈錠、王小亞、張雲、吳志全、夏榮強、緣朗投資合計持有的邁新生物95.55%的股權。
其中,上市公司擬受讓交易對方合計持有的標的公司65.55%的股權,國藥投資擬受讓交易對方合計持有的標的公司30%的股權。此次重大資產購買的實施與國藥投資參股權收購的實施互為前提。
此次交易完成後,邁新生物將成為上市公司的控股子公司。
根據中聯評估出具的《資產評估報告》,標的公司100%股權在評估基準日的評估值約27.57億元。參考前述《資產評估報告》中對標的公司100%股權的評估值,並經各方協商一致,標的公司100%股權作價確定為27.50億元,即此次交易的標的資產的交易價格確定為約18.03億元。
業績承諾期為2020年、2021年,業績承諾的補償義務方為各交易對方。補償義務人向上市公司承諾,標的公司在業績承諾期內的每年度的淨利潤不低於如下數額,且標的公司在業績承諾期合計實現的淨利潤不低於34282.14萬元,2020年度、2021年度承諾淨利潤分別不低於14250.42萬元、20031.72萬元。
此次交易後,上市公司將進一步強化在體外診斷試劑領域的佈局。通過收購邁新生物,上市公司業務將覆蓋腫瘤細胞篩查和手術後腫瘤組織切片的臨牀診斷領域,擴充病理診斷試劑和儀器產品線,提升技術研發能力和營銷網絡佈局,鞏固上市公司在體外診斷產業的領軍地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.